3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Endometrial Neoplasms
11
Uterine Cervical Neoplasms
5
Ovarian Neoplasms
4
Vulvar Neoplasms
3
Peritoneal Neoplasms
2
Uterine Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cervical Cancer Stage IB1
1
Carcinoma, Squamous Cell
1
Carcinoma, Ovarian Epithelial
1
Breast Neoplasms
1
Anus Neoplasms
1
Anastomotic Leak
1
Interventions
Cyclophosphamide
8
pembrolizumab
7
fludarabine
6
aldesleukin
4
Papillomavirus Vaccines
4
Vaccines
3
Radiotherapy
3
Light Coagulation
3
Biopsy
3
spartalizumab
2
fludarabine phosphate
2
entinostat
2
Watchful Waiting
2
Vorinostat
2
VGX-3100
2
Trastuzumab
2
Tomography, X-Ray Computed
2
Surveys and Questionnaires
2
Paclitaxel
2
Observation
2
Nivolumab
2
Interleukin-2
2
Interleukin-12 Subunit p35
2
Early Intervention, Educational
2
Drug Therapy
2
Carboplatin
2
Adoptive Transfer
2
trastuzumab deruxtecan
1
tislelizumab
1
tipifarnib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Anus Neoplasms
×
Indocyanine Green
×
Gynecologic
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled